# Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation

> **NCT07331727** · NA · NOT_YET_RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 280 (estimated)

## Conditions studied

- Atrial Fibrillation (AF)

## Interventions

- **DRUG:** Dapagliflozin (10Mg Tab) along with standard medical therapy

## Key facts

- **NCT ID:** NCT07331727
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07331727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07331727, "Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07331727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*